Roche lines up RNA pact with Remix Therapeutics, which also raised another $60M
Roche said Wednesday it will create new drugs with the help of RNA processing modulator Remix Therapeutics in a deal that involves $30 million upfront and $12 million in near-term milestones.
On top of the pact, which includes up to $1 billion in biobucks, Remix also disclosed a new $60 million financing round to help get the Boston-area biotech into the clinic.
The deal with Roche follows a tie-up of a similar size ($45 million upfront and more than $1 billion in milestones) with Johnson & Johnson that was announced in February 2022. Remix aims to degrade mRNA, boost RNA production or correct RNA dysregulation with its oral small molecules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
